Figure 4From: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402Establishment of gp100-specific CTL clones. The gp100-specific CTL clones were established in P2 and P3. Peptide-stimulated PBMCs with the ability to produce IFN-γ were expanded in the presence of feeder cells to establish gp100-specific CTL clones. Six clones were established (1 clone for P2, 3 clones for P3, and 2 clones for P4). A standard 4 h 51Cr-release assay was employed to confirm the anti-tumor response of these six clones. Representative results of the clones established from mP3 (P3-2, P3-3) are shown in the figure. All CTL clones were able to lyse A24-LCLs target cells pulsed with gp100-in4 (●), but not those pulsed with HLA-A*2402-resticted HIV peptide (□) in the left lane. They also were able to lyse 888 mel naturally expressing gp100 [gp100 (+), HLA-A24(+)]: (●) but not to lyse 397 mel [gp100 (+), HLA-A24(-)]: (□) and HT29 [gp100 (-), HLA-A24(+)]: (□).Back to article page